Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 juin 2025 09h42 HE | Source: PESG Research

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

On June 9th, PolyPid Ltd.* announced landmark topline results from its pivotal SHIELD II Phase 3 trial, demonstrating that D-PLEX100 achieved statistically significant reductions across all primary...
11 juin 2025 09h40 HE | Source: PESG Research

PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

On June 9th, PolyPid Ltd.* announced landmark topline results from its pivotal SHIELD II Phase 3 trial, demonstrating that D-PLEX100 achieved statistically significant reductions across all primary...
30 mai 2025 10h12 HE | Source: PESG Research

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid’s D-PLEX100 Approaches Critical Phase 3 Data Readout

New York, May 30, 2025 (GLOBE NEWSWIRE) -- PESG Research is releasing a report today examining PolyPid Ltd.*, an innovative late-stage biopharmaceutical company developing revolutionary localized...
22 mai 2025 15h46 HE | Source: PESG Research

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

New York, May 22, 2025 (GLOBE NEWSWIRE) -- PESG Research today announced the release of a report examining Silexion Therapeutics, an innovative biotechnology company developing unique RNA...